FORWARD I Phase 3 trial

October 7, 2019October 7, 2019

Mirvetuximab Soravtansine Effectively Delays Disease Progression in FRα-high Ovarian Cancers, Analysis Finds

News

ImmunoGen’s investigational therapy mirvetuximab soravtansine effectively delays disease progression in women with ovarian cancer who have high levels of the folate receptor alpha (FRα) protein, compared with chemotherapy, according to ... Read more

March 11, 2019

Mirvetuximab Soravtansine Fails to Delay Disease Progression in FRα-positive Ovarian Cancers, Trial Shows

News

Mirvetuximab soravtansine, an investigational antibody-drug conjugate targeting the folate receptor alpha (FRα) protein, was no better than chemotherapy at delaying disease progression or death in ovarian cancer patients included in ... Read more

June 27, 2018

Mirvetuximab Soravtansine Given FDA Fast Track Designation for Ovarian Cancer Treatment

News

Mirvetuximab soravtansine (IMGN853), an investigational antibody-drug conjugate, has been granted fast track designation by the U.S. Food and Drug Administration for the treatment of ovarian cancer patients, ImmunoGen, the therapy’s maker, announced. The ... Read more

May 7, 2018

Phase 3 Trial of Mirvetuximab Soravtansine in Ovarian Cancer OK’d to Continue as Planned

News

A Phase 3 trial evaluating ImmunoGen’s mirvetuximab soravtansine (IMGN853) in platinum-resistant ovarian cancer patients is on its way to achieving its objectives, an interim futility analysis shows. As a result, the FORWARD ... Read more

May 22, 2017

ImmunoGen’s Investigative Therapy for Ovarian Cancer Shows Potential in Clinical Studies

News

ImmunoGen will show promising safety and efficacy data of its investigative treatment mirvetuximab soravtansine for the treatment of FRα-positive epithelial ovarian cancer (EOC). The positive top-line data will be presented in three poster ... Read more

May 8, 2017

Phase 1 Trial of Ovarian Cancer Therapy Mirvetuximab Supports Phase 3 Study

News

Results from a Phase 1 clinical trial of mirvetuximab soravtansine (IMGN853) as a treatment for chemotherapy-resistant ovarian cancer and other malignancies have propelled the therapy into a Phase 3 trial. ... Read more